Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses

Main Article Content

Stephanie Renae Jackson Cullison
Burkhard Jansen
Zuxu Yao
Laura K Ferris

Keywords

melanoma, severely dysplastic nevi, non-invasive, gene expression, driver mutation, LINC/PRAME

Abstract

Background: Strategies to non-invasively detect cutaneous melanoma generally focus on differentiating melanoma from non-melanoma lesions. However, given the variabilities in practice and lack of guidelines, it is important for clinicians to understand how such strategies and technologies perform on borderline lesions of uncertain clinical behavior. 

Objective: To evaluate LINC and PRAME gene expression and the presence of somatic mutations in BRAF, NRAS, and/or TERT in severely dysplastic nevi (SDN) and to assess, how combining gene expression and mutation analyses may impact test performance.

Materials and Methods: One hundred three eligible skin lesions clinically suspicious for melanoma were non-invasively sampled via adhesive patches to enable genomic analyses. Afterward, these same lesions were immediately surgically biopsied to enable comparisons of genomic analyses with histopathologic diagnoses rendered by a panel of three dermatopathologists.  Twenty-three of these lesions analyzed were deemed borderline lesions of SDN histology by at least one dermatopathologist. RNA-based gene expression positivity by Pigmented Lesion Assay (PLA) analysis was defined by detectable levels of LINC and/or PRAME. DNA-based mutation positivity was defined as detection of somatic mutations in BRAF (non-V600E), NRAS, and/or the TERT promoter. 

Results: Adding TERT mutation analyses to PLA gene expression increases the test’s sensitivity to rule out melanoma from 93% to 97% in this study.  In addition, 61% of PLA positive lesions that were not diagnosed as melanoma were found to have severe histologic atypia. PLA-positive lesions histopathologically diagnosed as melanomas harbored TERT mutations in 70% of cases while both SDN and non-melanoma lesions including nevi without severe histologic atypia harbored TERT mutations in 4% of cases.  BRAF non-V600E and NRAS mutations were only found in the melanoma group and adding these mutations did not further enhance the test’s sensitivity. 

Conclusions and Relevance: PLA positivity increases with histologic atypia of pigmented skin lesions. Combining TERT mutation analyses with melanoma-associated gene expression provides additional genetic information to further non-invasively risk-stratify pigmented lesions.  These findings furthermore support that pigmented lesions exist on a spectrum of genomic atypia that may prove useful in identifying borderline lesions beyond their morphological appearance.

References

1. Shain AH, Yeh I, Kovalyshyn I et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 2015; 373(20):1926-1936.

2. Ferris LK, Gerami P, Skelsey MK et al. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. Melanoma Res 2018; 28(5):478-482.

3. Elmore JG, Barnhill RL, Elder DE et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 2017; 357:j2813.

4. Kim CC, Swetter SM, Curiel-Lewandrowski C et al. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA Dermatol 2015; 151(2):212-218.

5. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol 2012; 67(1):1 e1-16; quiz 17-18.

6. Engeln K, Peters K, Ho J et al. Dysplastic nevi with severe atypia: Long-term outcomes in patients with and without re-excision. J Am Acad Dermatol 2017; 76(2):244-249.

7. Gerami P, Yao Z, Polsky D et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol 2017; 76(1):114-120 e112.

8. Ferris LK, Jansen B, Ho J et al. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy. JAMA Dermatol 2017; 153(7):675-680.

9. Haqq C, Nosrati M, Sudilovsky D et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005; 102(17):6092-6097.

10. Ferris LK, Moy RL, Gerami P et al. Noninvasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma. J Invest Dermatol 2019; 139(5):1127-1134.

11. Duncan LM, Berwick M, Bruijn JA et al. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993; 100(3):318S-321S.

12. Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27-29, 1992. Consens Statement 1992; 10(1):1-25.

13. Culpepper KS, Granter SR, McKee PH. My approach to atypical melanocytic lesions. J Clin Pathol 2004; 57(11):1121-1131.

14. Nagore E, Heidenreich B, Requena C et al. TERT promoter mutations associate with fast-growing melanoma. Pigment Cell Melanoma Res 2016; 29(2):236-238.

15. Brouha B, Ferris LK, Skelsey MK et al. Real-world utility of a non-invasive gene expression test to rule out primary cutaneous melanoma: a large US registry study. JDD 2020; 19(3); doi:10.36849/JDD.2020.4766.

Most read articles by the same author(s)